Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Ferinject (ferric carboxymaltose)
DRUG
3 trials
Sponsors
Vifor Pharma
, National Cancer Center, Korea
Conditions
Anemia
Chronic Heart Failure
Iron Deficiency
Pancreatic Cancer
Phase 2
Efficacy of Ferric Carboxymaltose (Ferinject®) in Anemic Patients Anticipating Pancreatoduodenectomy
Completed
NCT02628860
National Cancer Center, Korea
Anemia, Pancreatic Cancer
Start: 2014-01-31
End: 2020-04-27
Updated: 2020-04-28
Phase 3
Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Iron Deficiency and Chronic Heart Failure
Completed
NCT01394562
Vifor Pharma
Chronic Heart Failure, Iron Deficiency
Start: 2011-07-31
End: 2016-05-31
Updated: 2017-05-18
Phase 4
A Study to Compare the Use of Ferric Carboxymaltose With Placebo in Patients With Chronic Heart Failure and Iron Deficiency
Completed
NCT01453608
Vifor Pharma
Chronic Heart Failure, Iron Deficiency
Start: 2011-10-31
End: 2015-01-31
Updated: 2015-03-18
Related Papers
Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency
Circulation
2017-07-12
409 citations
Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency
European Heart Journal
2014-08-31
1184 citations